Drug Trial Radar · NCT02849860
Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Dec 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Feb 2014
Primary completion
Sep 2016
Study completion Oct 2016
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant metabolites after topical dermal application of IDP-121 lotion.
Conditions
- Acne
Interventions
IDP-121 LotionDrug
Lotion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluators Global Severity Score at Day 15Time frame: 15 Days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Valeant Site 02
Austin, Texas
Valeant Site 01
College Station, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.